Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis
Portfolio Pulse from Benzinga Newsdesk
Ventyx Biosciences (NASDAQ:VTYX) has completed patient enrollment for its Phase 2 trials of VTX002 in ulcerative colitis and VTX958 in plaque psoriasis.
June 07, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ventyx Biosciences has completed enrollment for its Phase 2 trials of VTX002 in ulcerative colitis and VTX958 in plaque psoriasis, potentially bringing the company closer to advancing its novel oral therapies.
The completion of patient enrollment for the Phase 2 trials of VTX002 and VTX958 is a positive development for Ventyx Biosciences. This milestone brings the company closer to potentially advancing its novel oral therapies for inflammatory diseases with significant unmet medical need. As a result, this news may have a positive short-term impact on VTYX's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100